RxDoctor Payments Data

Cecil Sue-Wah-Sing, MD

Internal Medicine · Sun City Center, FLNPI 1003956616

Payments from drug & device makers

$2,321in general payments, 2019–2025

Across 25 payments — averaging $92.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$589
  • Johnson & Johnson$542
  • Novo Nordisk$472
  • Bayer$254
  • AstraZeneca$196
  • Janssen Scientific Affairs, LLC$100
  • plus $167 from 4 others

What the payments were for

  • Travel & lodging$37616%
  • Food & beverage$1,93884%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,321 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$72,150
Medicare patients
223
Services billed
821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$140,111
JardianceEmpagliflozin62$78,987
Breo ElliptaFluticasone/Vilanterol40$31,995
FarxigaDapagliflozin Propanediol14$21,034
Tresiba Flextouch U-100Insulin Degludec37$20,173
XareltoRivaroxaban16$20,112
JanuviaSitagliptin Phosphate12$19,452
OzempicSemaglutide18$18,456
Tresiba Flextouch U-200Insulin Degludec15$11,667
SymbicortBudesonide/Formoterol Fumarate16$8,622
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$6,858
Levothyroxine Sodium349$5,193
Gabapentin156$5,187
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,016
Levemir FlexpenInsulin Detemir17$4,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$12$142,892140 claims
AstraZenecaFarxiga, Symbicort$196$29,65630 claims
Johnson & JohnsonXarelto$542$20,11216 claims
Novo NordiskOzempic$472$18,45618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sun City Center

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →